Generating a Novel Transgenic Model and Developing Gene-Editing Therapeutic Approaches for Retinitis Pigmentosa

生成新型转基因模型并开发基因编辑治疗色素性视网膜炎的方法

• 批准号: 428839
• 负责人: Ghaseminejad Tafres Amirfarhad
• 金额: $ 1.27万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-12-01 至 2020-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=428839&lang=en
• 关键词: Crispr-Cas9; Crispr-Humanized Minimally Mouse Model; Gene-Editting; Light-Exacerbated Retinal Degeneration; Retinal Degeneration; Retinitis Pigmentosa; Rhodopsin; Rod Photoreceptors; T4k Rho Mutation; Xenopus Laevis

"Retinitis Pigmentosa (RP) is a vision-threatening disorder that is characterized by progressive blindness due to retinal degeneration (RD). According to Fighting Blindness Canada, 1 in 3500 Canadians are affected by this inherited retinal disease. Thousa

“视网膜色素变性（RP）是一种威胁视力的疾病，其特征是由于视网膜变性（RD）导致的进行性失明。根据加拿大致盲协会的数据，每3500名加拿大人中就有1人受到这种遗传性视网膜疾病的影响。拉瓜